|
|
Volumn 91, Issue 6, 2003, Pages 464-465
|
|
Zoledronic acid: A new advance in managing skeletal events in prostate cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ZOLEDRONIC ACID;
ANAMNESIS;
BONE DISEASE;
BONE METASTASIS;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
COHORT ANALYSIS;
CONFIDENCE INTERVAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DOSE TIME EFFECT RELATION;
DOUBLE BLIND PROCEDURE;
DRUG DOSE REGIMEN;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INFUSION;
DRUG MECHANISM;
DRUG POTENCY;
DRUG SAFETY;
DRUG SCREENING;
DRUG TOLERABILITY;
HUMAN;
KIDNEY FUNCTION;
MAJOR CLINICAL STUDY;
MALE;
MORBIDITY;
NOTE;
OSTEOLYSIS;
PAIN ASSESSMENT;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
PROSTATE CANCER;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
URINALYSIS;
ANTINEOPLASTIC AGENTS;
BONE NEOPLASMS;
DIPHOSPHONATES;
HUMANS;
IMIDAZOLES;
MALE;
PROSTATIC NEOPLASMS;
|
|
EID: 0038367515
PISSN: 14644096
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1464-410X.2003.04142.x Document Type: Note |
|
Times cited : (2)
|
|
References (5)
|
